RS51069B - Upotreba oksikodona za tretiranje visceralnog bola - Google Patents

Upotreba oksikodona za tretiranje visceralnog bola

Info

Publication number
RS51069B
RS51069B RSP-2009/0553A RSP20090553A RS51069B RS 51069 B RS51069 B RS 51069B RS P20090553 A RSP20090553 A RS P20090553A RS 51069 B RS51069 B RS 51069B
Authority
RS
Serbia
Prior art keywords
oxycodone
pain
pharmaceutically acceptable
use according
dosage form
Prior art date
Application number
RSP-2009/0553A
Other languages
English (en)
Serbian (sr)
Inventor
Asbjorn Mohr Drewes
Lars Arendt Nielsen
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51069(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of RS51069B publication Critical patent/RS51069B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
RSP-2009/0553A 2005-01-18 2006-01-17 Upotreba oksikodona za tretiranje visceralnog bola RS51069B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Publications (1)

Publication Number Publication Date
RS51069B true RS51069B (sr) 2010-10-31

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0553A RS51069B (sr) 2005-01-18 2006-01-17 Upotreba oksikodona za tretiranje visceralnog bola

Country Status (31)

Country Link
US (2) US20080200493A1 (enExample)
EP (1) EP1838318B1 (enExample)
JP (1) JP5049139B2 (enExample)
KR (10) KR20230170811A (enExample)
CN (1) CN101106996B (enExample)
AP (1) AP2249A (enExample)
AR (1) AR052880A1 (enExample)
AT (2) ATE446092T1 (enExample)
AU (1) AU2006207498B2 (enExample)
BR (1) BRPI0606247A2 (enExample)
CA (1) CA2595043C (enExample)
CY (1) CY1109660T1 (enExample)
DE (2) DE202006019887U1 (enExample)
DK (2) DK1838318T3 (enExample)
EA (1) EA013544B1 (enExample)
ES (1) ES2333901T3 (enExample)
HR (1) HRP20090679T1 (enExample)
IL (1) IL184530A (enExample)
ME (1) ME01066B (enExample)
MX (1) MX2007007207A (enExample)
MY (1) MY144471A (enExample)
NO (1) NO338968B1 (enExample)
NZ (1) NZ555852A (enExample)
PL (1) PL1838318T3 (enExample)
PT (1) PT1838318E (enExample)
RS (1) RS51069B (enExample)
SI (1) SI1838318T1 (enExample)
TW (1) TWI432196B (enExample)
UA (1) UA85471C2 (enExample)
WO (1) WO2006077212A1 (enExample)
ZA (1) ZA200705231B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3045182T3 (en) 2005-11-14 2018-03-19 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
IN2012DN02521A (enExample) 2009-08-28 2015-08-28 Rinat Neuroscience Corp
TR201904088T4 (tr) 2011-05-20 2019-05-21 Alderbio Holdings Llc Anti-CGRP bileşimleri ve bunların kullanımları.
BR112013029951B1 (pt) 2011-05-20 2020-10-20 Alderbio Holdings Llc composição farmacêutica e uso de anticorpos ou fragmentos de anticorpos anti-cgrp para tratar ou prevenir formas de diarreia crônicas e agudas
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US9896502B2 (en) 2014-03-21 2018-02-20 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
MA54704A (fr) 2019-01-08 2022-04-13 H Lundbeck As Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
SG10202003296VA (en) 2020-04-06 2021-11-29 H Lundbeck As Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
CN1146421C (zh) * 1996-03-25 2004-04-21 伊莱利利公司 治疗疼痛的组合物以及药物在制备所述组合物中的应用
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
ES2333901T3 (es) 2010-03-02
AP2249A (en) 2011-07-18
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
HK1107933A1 (en) 2008-04-25
NO20074174L (no) 2007-10-17
MY144471A (en) 2011-09-30
KR20190135557A (ko) 2019-12-06
NO338968B1 (no) 2016-11-07
KR20220165797A (ko) 2022-12-15
JP5049139B2 (ja) 2012-10-17
AT9895U1 (de) 2008-05-15
TWI432196B (zh) 2014-04-01
AU2006207498A1 (en) 2006-07-27
DK1838318T3 (da) 2010-01-04
UA85471C2 (ru) 2009-01-26
KR20120089710A (ko) 2012-08-13
ATE446092T1 (de) 2009-11-15
AR052880A1 (es) 2007-04-11
US20150190393A1 (en) 2015-07-09
ME01066B (me) 2012-10-20
PL1838318T3 (pl) 2010-03-31
IL184530A (en) 2015-01-29
EP1838318B1 (en) 2009-10-21
DK200700207U3 (da) 2007-09-28
AU2006207498B2 (en) 2009-11-19
PT1838318E (pt) 2009-12-15
ZA200705231B (en) 2008-06-25
CA2595043A1 (en) 2006-07-27
TW200637554A (en) 2006-11-01
KR20200128451A (ko) 2020-11-12
DE602006009899D1 (de) 2009-12-03
CN101106996A (zh) 2008-01-16
SI1838318T1 (sl) 2010-02-26
EP1838318A1 (en) 2007-10-03
EA200701541A1 (ru) 2008-02-28
EA013544B1 (ru) 2010-06-30
WO2006077212A1 (en) 2006-07-27
CY1109660T1 (el) 2014-08-13
JP2008526927A (ja) 2008-07-24
US9271974B2 (en) 2016-03-01
US20080200493A1 (en) 2008-08-21
KR20210131450A (ko) 2021-11-02
DE202006019887U1 (de) 2007-07-26
KR20070100368A (ko) 2007-10-10
KR20230170811A (ko) 2023-12-19
CA2595043C (en) 2013-11-19
DK200700207U1 (da) 2007-08-24
AP2007004057A0 (en) 2007-08-31
KR20140091782A (ko) 2014-07-22
KR20080106991A (ko) 2008-12-09
IL184530A0 (en) 2007-10-31
NZ555852A (en) 2010-01-29
HRP20090679T1 (hr) 2010-01-31
CN101106996B (zh) 2013-10-23
BRPI0606247A2 (pt) 2009-06-09

Similar Documents

Publication Publication Date Title
US9271974B2 (en) Use of oxycodone for treating visceral pain
JP3375960B2 (ja) 制御放出オキシコドン組成物
KR20070107805A (ko) 옥시코돈 및 날록손 함유 제형
PT2266564E (pt) Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
JP2013537915A (ja) オピオイドの制御放出製剤
NZ763555A (en) Delayed release deferiprone tablets and methods of using the same
JP2022540917A (ja) 治療的処置のためのガボキサドール含有医薬製剤
HK1107933B (en) Use of oxycodone for treating visceral pain
RS50053B (sr) Oksikodonski preparati koji se kontrolisano ispuštaju